In the last trading session, 2.3 million shares of the Protara Therapeutics Inc (NASDAQ:TARA) were traded, and its beta was 1.72. Most recently the company’s share price was $6.67, and it changed around $0.76 or 12.86% from the last close, which brings the market valuation of the company to $135.08M. TARA currently trades at a discount to its 52-week high of $10.48, offering almost -57.12% off that amount. The share price’s 52-week low was $1.37, which indicates that the current value has risen by an impressive 79.46% since then. We note from Protara Therapeutics Inc’s average daily trading volume that its 10-day average is 11.99 million shares, with the 3-month average coming to 2.02 million.
Protara Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended TARA as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight.
Protara Therapeutics Inc (NASDAQ:TARA) trade information
Instantly TARA has showed a green trend with a performance of 12.86% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 10.48 on recent trading dayincreased the stock’s daily price by 36.35%. The company’s shares are currently up 255.71% year-to-date, but still up 163.64% over the last five days. On the other hand, Protara Therapeutics Inc (NASDAQ:TARA) is 162.60% up in the 30-day period. We can see from the shorts that 2.74 million shares have been sold at a short interest cover period of 14.46 day(s).
Protara Therapeutics Inc (TARA) estimates and forecasts
Protara Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 148.88 percent over the past six months and at a 16.25% annual growth rate that is well below the industry average of 16.80%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 39.98%.
TARA Dividends
Protara Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Protara Therapeutics Inc (NASDAQ:TARA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.13% of Protara Therapeutics Inc shares, and 51.11% of them are in the hands of institutional investors. The stock currently has a share float of 54.45%. Protara Therapeutics Inc stock is held by 45.0 institutions, with OPALEYE MANAGEMENT INC. being the largest institutional investor. By 2024-06-30, it held 20.1758% of the shares, which is about 2.3 million shares worth $5.3 million.
RA CAPITAL MANAGEMENT, L.P., with 16.6361% or 1.9 million shares worth $3.95 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
